Page 7 - hypertension_newsletter (5)

REFLECTIONS rtensio n
Hypertension Global Newsletter #2 Hype
Hype
A total of 44 studies were included that reported
on adults with hypertension aged =18 years n oisnetr
receiving SPC or FEC hypertensive therapy
and measured any of the following: adherence,
persistence, and reductions in systolic and/
or diastolic BP. The majority of studies that
measured particular outcomes showed that
SPC led to significantly improved adherence
and persistence. In the nine articles that
measured if patients achieved BP targets, the
majority showed a numerical or significant
improvement with SPC therapy.

The authors suggest that physicians should
consider SPC therapy early or as first-line
therapy, as this approach may be more cost-
effective, reduce physician clinical inertia,
improve medication adherence and medication
persistence, and ultimately improve BP control.

CLICK HERE
FOR THE LINK TO FULL
ARTICLE

Nonadherence in hypertension: How to develop and implement chemical
adherence testing.

Lane D, et al. Hypertension. 2022;79(1):12-23.

Nonadherence to antihypertensive medications is common
(~30–50%) and is associated with uncontrolled BP and
poor clinical outcomes. Routine detection of nonadherence
is supported by clinical guidelines. Chemical adherence
testing, which uses liquid chromatography-tandem mass
spectrometry to detect medications in patient samples such
as blood or urine, is a reliable and valid method to detect
adherence, but there are currently no standardized methods
for the process. This article aims to provide standardized
principles and a set of recommendations for centres wishing
to implement chemical adherence testing.

The recommendations for developing and implementing
adherence testing outline how chemical adherence testing
should be conducted, who are appropriate patients that may
benefit from it, the platform to use for the analysis, and details
on the reporting of the results, including how and when to
communicate the results with patients.

TABLE OF CONTENTS